Ricardo Garcia Branco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ricardo Garcia Branco has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Celiny Ramos Garcia
Pontifícia Universidade Católica do Rio Grande do Sul, Brazil
2 shared publications Alberto Ballestrero
IRCCS Ospedale Policlinico San Martino, Genoa, Italy
1 shared publicationAlberto Garbarino
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy
1 shared publication- Ali Ait Hssain
Medical Intensive Care Unit, Hamad General Hospital, Doha, Qatar; Department of Medicine, Weill Cornell Medical College, Doha, Qatar; College of Health and Life Science, Hamad Bin Khalifa University, Doha, Qatar
1 shared publication Andrea De Maria
IRCCS Ospedale Policlinico San Martino, Genoa, Italy
1 shared publicationAndrea Lucia Machado Barcelos
Universidade Federal de Santa Maria, Santa Maria, Brazil
1 shared publication
Latest Publications
- Open Access
- 11 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (45) , eabp9961
High–temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines
Knowledge of the mechanisms underpinning the development of protective immunity conferred by mRNA vaccines is fragmentary. Here, we investigated responses to coronavirus disease 2019 (COVID-19) mRNA vaccination via high–temporal resolution blood transcriptome profiling. The first vaccine dose elicited modest interferon and adaptive immune responses, which peaked on days 2 and 5, respectively. The second vaccine dose, in contrast, elicited sharp day 1 interferon, inflammation, and erythroid cell responses, followed by a day 5 plasmablast response. Both post-first and post-second dose interferon signatures were associated with the subsequent development of antibody responses. Yet, we observed distinct interferon response patterns after each of the doses that may reflect quantitative or qualitative differences in interferon induction. Distinct interferon response phenotypes were also observed in patients with COVID-19 and were associated with severity and differences in duration of intensive care. Together, this study also highlights the benefits of adopting high-frequency sampling protocols in profiling vaccine-elicited immune responses.
- 11 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (45) , eabp9961
Open AccessHigh–temporal resolution profiling reveals distinct immune trajectories following the first and second doses of COVID-19 mRNA vaccines
Knowledge of the mechanisms underpinning the development of protective immunity conferred by mRNA vaccines is fragmentary. Here, we investigated responses to coronavirus disease 2019 (COVID-19) mRNA vaccination via high–temporal resolution blood transcriptome profiling. The first vaccine dose elicited modest interferon and adaptive immune responses, which peaked on days 2 and 5, respectively. The second vaccine dose, in contrast, elicited sharp day 1 interferon, inflammation, and erythroid cell responses, followed by a day 5 plasmablast response. Both post-first and post-second dose interferon signatures were associated with the subsequent development of antibody responses. Yet, we observed distinct interferon response patterns after each of the doses that may reflect quantitative or qualitative differences in interferon induction. Distinct interferon response phenotypes were also observed in patients with COVID-19 and were associated with severity and differences in duration of intensive care. Together, this study also highlights the benefits of adopting high-frequency sampling protocols in profiling vaccine-elicited immune responses.
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 632-637
Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children
- 1 February 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 40 (2) , 632-637
Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children
- Open Access
- 19 February 2020
- Published by BMJ in Archives of Disease in Childhood
- Vol. 106 (3) , 286-289
Accuracy of cerebrospinal fluid ferritin for purulent meningitis
Objective To evaluate the use of cerebrospinal fluid (CSF) ferritin levels in the diagnosis of purulent meningitis (PM). Method We studied 81 children between 28 days and 12 years of age who presented with clinical suspicion of meningitis to the emergency department. CSF ferritin levels were measured and compared between diagnostic groups (PM, aseptic meningitis (AM) and no meningitis). Results The median age was 24 (IQR 8–69) months. There were 32 patients with AM (39%), 23 with PM (28%) and 26 with no meningitis (32%). Median CSF ferritin was 4.2 ng/mL (IQR 3.0–6.5), 52.9 ng/mL (IQR 30.7–103 ng/mL) and 2.4 ng/mL (IQR 2–4), respectively. CSF ferritin was higher in children with PM compared with AM (pConclusion CSF ferritin may be a useful biomarker to discriminate PM in children with clinical symptoms of this disease.
- 19 February 2020
- Published by BMJ in Archives of Disease in Childhood
- Vol. 106 (3) , 286-289
Open AccessAccuracy of cerebrospinal fluid ferritin for purulent meningitis
Objective To evaluate the use of cerebrospinal fluid (CSF) ferritin levels in the diagnosis of purulent meningitis (PM). Method We studied 81 children between 28 days and 12 years of age who presented with clinical suspicion of meningitis to the emergency department. CSF ferritin levels were measured and compared between diagnostic groups (PM, aseptic meningitis (AM) and no meningitis). Results The median age was 24 (IQR 8–69) months. There were 32 patients with AM (39%), 23 with PM (28%) and 26 with no meningitis (32%). Median CSF ferritin was 4.2 ng/mL (IQR 3.0–6.5), 52.9 ng/mL (IQR 30.7–103 ng/mL) and 2.4 ng/mL (IQR 2–4), respectively. CSF ferritin was higher in children with PM compared with AM (pConclusion CSF ferritin may be a useful biomarker to discriminate PM in children with clinical symptoms of this disease.
- 1 October 2004
- Published by Elsevier in Pediatric Neurology
- Vol. 31 (4) , 309
CSF ferritin as a marker for bacterial meningitis
- 1 October 2004
- Published by Elsevier in Pediatric Neurology
- Vol. 31 (4) , 309
CSF ferritin as a marker for bacterial meningitis